pilocarpine/headache

Thirty-one patients with cluster headache were examined with regard to their forehead sweating pattern, by means of the Evaporimeter. Sweating was stimulated in two different ways: by body heating and by parenterally administered pilocarpine. The resulting increase in evaporation was frequently

A comparison of the heat- and pilocarpine-induced forehead sweating patterns was carried out in 8 patients with "Hemicrania continua" (HC) and in healthy subjects (n = 17 and 14 for the two tests, respectively). The results were compared with those obtained in 8 patients with chronic paroxysmal

In eight patients with chronic paroxysmal hemicrania (CPH), forehead sweating was measured after various provocation tests-body heating, exercise, and subcutaneous pilocarpine administration (0.1 mg/kg body weight). Evaporation was measured bilaterally on the forehead with an Evaporimeter (in

Twenty-nine patients with cluster headache have been examined with the pupillometer and the evaporimeter. Pupils were dilated by sympathicomimetic drugs instilled into the conjunctival sacs, and responses of the two sides were compared. Forehead sweating was stimulated by body heating and by

OBJECTIVE To evaluate the comparative efficacy of latanoprost monotherapy versus combined carteolol and pilocarpine therapy in patients with newly diagnosed glaucoma. METHODS Masked randomized prospective trial. This study included 51 patients (64 eyes) with newly diagnosed glaucoma or ocular

In cluster headache, forehead sweating is frequently pathological and for this reason it is important to know the normal pattern. In the present work, sweating was induced by exercise and pilocarpine in 14 healthy individuals in the age group 24-50 years. A comparison was also made with patterns of

OBJECTIVE To compare the effect on intraocular pressure (IOP) of latanoprost monotherapy and timolol-pilocarpine in patients with glaucoma or ocular hypertension with inadequately controlled IOP on topical beta adrenergic antagonists. METHODS This was a multicentre, randomised, observer masked, 6

Eighteen cluster headache patients were studied using body heating or exercise tests; all but two of them were also studied with a pilocarpine test (0.1 mg/kg body wt, s.c.). Evaporimeter measurements were made on both sides of the forehead under standard conditions in a thermo room. Heat- and

Forehead sweating in 11 patients with cervicogenic headache was tested with the Evaporimeter. All were studied during heating experiments, 2 patients during exercise, and 10 patients after pilocarpine stimulation. Five patients were studied during spontaneous attacks. The evaporation during

Attacks of cluster headache are often associated with symptoms of an autonomic nature. A test battery allowing quantitation of salivation, nasal secretion and tearing has been employed. Fourteen patients examined under basal conditions hardly differed from a group of controls (N = 20). After

Autonomic functions have been studied in seven patients with chronic paroxysmal hemicrania (CPH). A test battery comprising tearing, salivation and nasal secretion was employed. Under basal conditions these parameters did not differ significantly from those in a control group. After stimulation with

Pupillometric studies were carried out in eight patients with chronic paroxysmal hemicrania (CPH) and in age- and sex-matched controls in the basal condition and after instillation of 2% tyramine (CPH, n = 5; controls, n = 17), 1% OH-amphetamine (CPH, n = 6; controls, n = 12), and 1% phenylephrine

Xerostomia complaint is very commonly associated to radioactive iodine therapy. Alternatives to treat this morbidity can offer better quality of life to patients with thyroid cancer submitted to adjuvant iodine therapy. OBJECTIVE to report on the experience with pilocarpine on the treatment of

OBJECTIVE To evaluate the ocular hypotensive efficacy and safety of a fixed combination of betaxolol (0.25%) and pilocarpine (1.75%). METHODS Three multicenter, double-masked, parallel trials were completed in patients with primary open-angle glaucoma or ocular hypertension of 3 months' treatment